Schonfeld Strategic Advisors’s Elevai Labs ELAB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ELAB Stock Details ELAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,480	Closed	-$88.7K	–	2712
2026 Q1	$88.7K	Buy	+1,480	New	+$190K	﹤0.01%	1906

Other funds holding ELAB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Schonfeld Strategic Advisors's ELAB Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Elevai Labs (ELAB) in Q2 2026, closing a stake of 1,480 shares — an estimated $88.7K sold.

Schonfeld Strategic Advisors first reported a position in ELAB in Q1 2026 and held it in 1 quarter. The position peaked at $88.7K in Q1 2026. 11 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

Schonfeld Strategic Advisors reported no remaining Elevai Labs position as of Q2 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 1,480 Elevai Labs shares in Q2 2026, an estimated $88.7K.
Schonfeld Strategic Advisors first reported a position in Elevai Labs in Q1 2026 and held it in 1 quarter.
Schonfeld Strategic Advisors's Elevai Labs position peaked at $88.7K in Q1 2026.
11 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.